An ASCO leadership development project to understand barriers to clinical cancer research in the Asia-Pacific. Disparities in African-American patient enrollment in pivotal phase 3 immunotherapy ...
Patients with ECOG performance status of 1 reported worse global health status, quality of life, and physical functioning than those with a status of 0. The RATIONALE-305 trial showed Tevimbra plus ...
ECOG performance status is an important risk factor for early mortality in metastatic castration-resistant prostate cancer (mCRPC). Patients with metastatic castration-resistant prostate cancer (mCRPC ...
Please provide your email address to receive an email when new articles are posted on . Chemoimmunotherapy extended PFS compared with chemotherapy for patients with extensive-stage small cell lung ...
Identification of factors related to immunotherapy prognosis in patients with advanced head and neck squamous cell carcinoma. MVX-ONCO-1 in advanced refractory cancers: Safety, feasibility, and ...
Incorporating ICIs into platinum-doublet regimens improved OS and ORR in ES-SCLC patients with ECOG PS 2 to 3, but not in those with ECOG PS 0 to 1. The study found manageable adverse reactions, with ...
Chemoimmunotherapy was tested in patients with extensive-stage small cell lung cancer to determine its effect based on different performance statuses. Patients with extensive-stage small cell lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results